Daniel Kenny joined OncoSil Medical in January 2015 with almost 30 years’ experience in the Global Pharmaceutical and Medical Device industry.
Daniel is an accomplished and proven biopharmaceutical business leader and in his career he has developed and successfully driven business with industry leaders such as Roche, Allergan and Baxter working in Australia, EMEA and the US.
Prior to joining OncoSil Medical, Daniel held the position of Chief Commercial Officer at ABIVAX a Paris based global biopharmaceutical company specialising in the development of novel vaccines and anti-virals.
At Baxter Daniel served as Global Franchise Head Vaccines overseeing all Franchise Operations. Before this role, Daniel served as Vice President Baxter BioScience, EMEA with responsibility for all marketing and key business programmes in support of regional sales exceeding $1.9bio.
Daniel also served with Roche as Global LifeCycle Leader for Roaccutance, a product generating sales in excess of CHF 1.1 bio (2002) assuming responsibility for all global strategic marketing and business development activities. Prior to this role he was International Medical Manager and Medical Science and Safety Team leader responsible for post NDA clinical development strategy and critical issue work ups for regulatory authorities.
Daniel completed over 10 years in clinical research in the fields of Ophthalmology with the Royal Australian College of Ophthalmologists and the University of Sydney and HIV/AIDS research at the University of New South Wales, Sydney, Australia prior to joining the pharmaceutical industry.
Daniel is a graduate in Physics from the University of New South Wales and has completed Executive business studies at both INSEAD and London Business School. He is a graduate of the Australian Institute of Physics and is a member of the Australian Institute of Company Directors.
CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY
Tom Milicevic is an experienced commercial, financial and management accountant with more than 20 years’ experience working with a number of major Australian and international public companies.
He has specific financial expertise in medical device and biotech companies and his appointment represents a pivotal hire for the Company as it transitions from a development focus to the commercialisation of its OncoSillocalised radiation treatment for cancer.
Prior to joining OncoSil Medical Tom was CEO and CFO of orthopaedic medical device company, Allegra Orthopaedics Limited (ASX: AMT) and successfully led the Company through its IPO and ASX listing. Mr Milicevic was also CFO for Babcock & Brown Residential Land Partners, an ASX listed fund, where he was the financial lead on the stapled security’s $175m IPO.
His previous roles include CFO and Company Secretary with an ASX listed oncology biotech, and senior finance and accounting roles with ASX 100 Australian companies.
Tom is a qualified Certified Practising Accountants (CPA) and a Fellow of the Australian Society of CPA’s. He also has a Bachelor of Commerce from the Western Sydney University, and has completed a MBA at Macquarie Graduate School of Management in Sydney.
GLOBAL HEAD OF MANUFACTURING OPERATIONS
David James is a highly experienced pharmaceutical manufacturing operations executive with more than 25 years’ experience in this field, including six years with leading cancer treatment company Sirtex Medical (ASX: SRX) as Global Operations Manager.
During his time at Sirtex, David was responsible for managing the global operations team including production, logistics, customer service, and engineering. This included responsibility for the design, construction, and commissioning of Sirtex’s first in-house manufacturing plant in Wilmington DC, in the US.
David has a Masters in Business and Technology from the University of New South Wales, and a Bachelor of Science from the University of Newcastle. David is a Chartered Chemist with the Royal Australian Chemical Institute and managed his own consultancy business before joining Oncosil.
DIRECTOR SALES AND MARKETING
Michael Warrener has over 15 consecutive years experience in the implantable radioactive microspheres space in treatment of liver cancer, joining Sirtex Medical in 2002 and most recently in the treatment of pancreas cancer with Oncosil Medical. His responsibilities have been focused on the commercialisation of these innovative therapies and include 5 years with Sirtology focused on product design development, quality management, regulatory and design dossier submissions for CE Marking in the European Union.
Michael moved from Sirtex Sydney to Bonn, Germany in 2003 as the European Director Sales and Marketing to establish the EU market as well as Scandanavian countries and a number of middle eastern countries.
VP REGULATORY AND QA
Nicole Wilson is a former Sirtex Medical Global Regulatory Affairs Manager with 10 years Regulatory Medical Device experience.
She is a Regulatory Affairs specialist focused on quality compliance and marketing registrations in the Asia, South America and middle East.
Principal for the regulatory approvals in Brazil, Argentina and UAE for Sirtex.
PRESIDENT OF US OPERATIONS
Charles Rowland has had a successful career building and commercialisingearly stage medical device companies, predominantly in the interventional oncology and cardiology industries.
Prior to joining OncoSil Medical, Charles has launched the US subsidiary for Sirtex Medical and built a highly successful sales, marketing and operations team. In his role he developed strong relationships with many leading US cancer hospitals and with key physicians in the field. During his four years with Sirtex, the US operations grew from zero to over $15 million accounting for almost 80% of the company’s global revenues. He has served on the Sirtex Board of Directors.
Charles has held senior leadership positions at other early stage medical device companies. He co-founded and raised private funding for Ralin Medical/LifeWatch, a cardiac device and patient monitoring company which grew to around $20 million in revenues and was purchased by CardGuard.